Risk Management



Several New and Revised Consent Forms Published by OMIC

Several new and revised informed consent documents and risk management recommendations documents were recently uploaded.

CATARACT SURGERY

  • New: Same Day Sequential Bilateral Surgery Addendum
  • New: Femtosecond Laser Cataract Surgery Addendum

RETINA

  • New: Intravitreal Anti-VEGF Injections for Adults: Risk Management Recommendations
  • Revised: AvastinTM (bevacizumab) Consent
  • Revised: EyleaTM (aflibercept) Consent
  • Revised: LucentisTM (ranibizumab) Consent
  • Revised: OzurdexTM (dexamethasone) Consent

RETINOPATHY OF PREMATURITY

  • New: Intravitreal Anti-VEGF Injections for ROP: Risk Management Recommendations
  • Revised: Intravitreal Anti-VEGF Injections for ROP Consent

See all new consent forms here.

See all new risk management recommendation guides here.

OMIC policyholders who adminster intravitreal anti-VEGF (IVAV) injections for ROP are strongly encouraged to review these forms and contact OMIC Risk Manager Anne M. Menke, RN, PhD, if you use IVAV for indications not listed on the consent form, or if you have any questions about ROP. She may be reached at 1.800.562-6642, extension 651 or amenke@omic.com.

Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Leave a comment



scales

Six reasons OMIC is the best choice for ophthalmologists in America.

#3. Best at defending claims.

An ophthalmologist pays nearly half a million dollars in premiums over the course of a career. Premium paid is directly related to your carrier’s claims experience. OMIC has a higher win rate taking tough cases to trial, full consent to settle (no hammer) clause, and access to the best experts. OMIC pays 25% less per claim than other carriers. As a result, OMIC’s base rates have consistently averaged approximately 15% lower than multispecialty carriers in the U.S.

61864684